Ibacache-Figueroa ME

Idioma: Español
Referencias bibliográficas: 7
Paginas: 251-253
Archivo PDF: 149.16 Kb.

FRAGMENTO

Los α₂-agonistas componen un grupo de fármacos que se unen a receptores a₂-adrenérgicos y, a partir de esta unión, producen modificaciones moleculares en las células que los expresan, dando curso a una extensa y variada gama de efectos.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Bylund D. Pharmacological characteristics of alpha-2 adrenergic receptor subtypes. Ann N Y Acad Sci. 1995;763:1-7.

2. Berkowitz D, Price D, Bello E, Page S, Schwinn D. Localization of messenger RNA for three distinct alpha 2-adrenergic receptor subtypes in human tissues. Evidence for species heterogeneity and implications for human pharmacology. Anesthesiology. 1994;81:1235-1244.

3. Lorenz W, Lomasney J, Collins S, Regan J, Caron M, Lefkowitz R. Expression of three a2-adrenergic receptor subtypes in rat tissues: implications for a2 receptor classification. Mol Pharmacol. 1990;38:599-603.

4. Chalikonda SA. Alpha 2-adrenergic agonists and their role in the prevention of perioperative adverse cardiac events. AANA Journal. 2009;77:103-108.

5. Rockman HA, Koch WJ, Lefkowitz RJ. Seven-transmembrane-spanning receptors and heart function. Nature. 2002;415: 206-212.

6. Ibacache M, Sanchez G, Pedrozo Z, Galvez F, Humeres C, Echevarria G, et al. Dexmedetomidine preconditioning activates pro-survival kinases and attenuates regional ischemia/reperfusion injury in rat heart. Biochim Biophys Acta. 2012;1822:537-545.

7. Cai Y, Xu H, Yan J, Zhang L, Lu Y. Molecular targets and mechanism of action of dexmedetomidine in treatment of ischemia/reperfusion injury. Mol Med Rep. 2014;9:1542-1550.